Relative Strength Chart Johnson & Johnson

Equities

Market Closed - Nyse Other stock markets 02:30:02 15/01/2026 am IST			5-day change	1st Jan Change
218.55 ^USD	+2.29%		+5.33%	+5.61%

15/01	Tecvayli monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide	RE
15/01	Johnson & Johnson Reports 71% Risk Reduction for Tecvayli in Phase 3 Myeloma Study	MT

End-of-day quotes

		Sector	Change	5d. change	Varia. Jan 1.	1-year change	5-years change	Capi.	ST	MT	LT
	JOHNSON & JOHNSON	Other Pharmaceuticals	+2.29%	+5.33%	+5.61%	+50.98%	+36.04%	53TCr